Qihong Zhao

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression
    Qihong Zhao
    Department of Immunology, Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08540, USA
    Int Immunopharmacol 3:1803-17. 2003
  2. ncbi request reprint Inflammation, autoimmunity, and atherosclerosis
    Qihong Zhao
    Research and Development, Bristol Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
    Discov Med 8:7-12. 2009
  3. doi request reprint Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases
    Qihong Zhao
    Research and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, USA
    J Leukoc Biol 88:41-55. 2010
  4. pmc Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe
    Percy H Carter
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Proc Natl Acad Sci U S A 104:6846-51. 2007
  5. doi request reprint gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists
    Robert J Cherney
    Research and Development, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 20:2425-30. 2010
  6. doi request reprint Clinically validated approaches to the treatment of autoimmune diseases
    Percy H Carter
    Bristol Myers Squibb Company, Research and Development, Rt 206 and Province Line Road, Princeton, NJ 08543, USA
    Expert Opin Investig Drugs 19:195-213. 2010

Detail Information

Publications6

  1. ncbi request reprint Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression
    Qihong Zhao
    Department of Immunology, Bristol Myers Squibb, Route 206 and Province Line Road, Princeton, NJ 08540, USA
    Int Immunopharmacol 3:1803-17. 2003
    ..These results have clearly demonstrated, for the first time, an effect of receptor density on the agonist and antagonist properties of RU486 and MPA in GR-mediated transrepression...
  2. ncbi request reprint Inflammation, autoimmunity, and atherosclerosis
    Qihong Zhao
    Research and Development, Bristol Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
    Discov Med 8:7-12. 2009
    ....
  3. doi request reprint Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases
    Qihong Zhao
    Research and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, USA
    J Leukoc Biol 88:41-55. 2010
    ..It also examines potential safety issues associated with such dual targeting...
  4. pmc Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe
    Percy H Carter
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Proc Natl Acad Sci U S A 104:6846-51. 2007
    ..These studies led to the identification of the benzoxazepinone SW106, a previously unrecognized small molecule antagonist for the PPR. The binding of SW106 to the PPR was rationalized by using a homology receptor model...
  5. doi request reprint gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists
    Robert J Cherney
    Research and Development, Bristol Myers Squibb Company, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 20:2425-30. 2010
    ..0 nM and chemotaxis IC(50) = 0.5 nM) and improved metabolic stability over its parent glycinamide...
  6. doi request reprint Clinically validated approaches to the treatment of autoimmune diseases
    Percy H Carter
    Bristol Myers Squibb Company, Research and Development, Rt 206 and Province Line Road, Princeton, NJ 08543, USA
    Expert Opin Investig Drugs 19:195-213. 2010
    ..Although many of these diseases are rare, the collective prevalence of autoimmune diseases in the United States alone is between 5 and 8%, and is increasing...